Clinical trials: Solar Urticaria
Idiopathic Solar Urticaria
Evaluation of the Protection Activity of Microfine Titanium Dioxide (Ti02), Pigmentary Ti02 and Bisoctrizole and Their Combinations in Voluntary Patients With Idiopathic Solar Urticaria (SU)
Commercially available external photoprotectors (EP) do not provide adequate protection against ultraviolet A (UVA) and visible wavelengths.
- Trial name
- NCT00483496
- Testing
- Titanium dioxide (Ti02) microfine 12.15% alone (formula RV3131A-MV1209), Ti02 pigmentary 3% alone (formula RV3131A-MV1211), bisoctrizole 10% alone (formula RV3131A-MV1237)
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 16 people
- Sponsor
- Orfagen
Solar Urticaria
Omalizumab in Severe and Refractory Solar Urticaria
Solar urticaria is a rare disease, with a usual favourable outcome with photoprotection and with anti H1 histamines. Nevertheless, some cases can be severe and refractory to this usual treatment, leading to a large impact on…
- Trial name
- XOLUS (NCT02262130)
- Testing
- Omalizumab
- Where
- 13 sites in France
- Volunteers
- 10 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon